Thyroid Gland Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the follicular cells of the thyroid gland. According to the degree of differentiation, it is classified either as differentiated carcinoma (extensive evidence of follicular cell differentiation), or poorly differentiated carcinoma (limited evidence of follicular cell differentiation). 
Thyroid gland adenocarcinomas most frequently harbor alterations in BRAF, NRAS, TP53, HRAS, and ATM .
BRAF Mutation, BRAF Exon 15 Mutation, BRAF V600E, BRAF Codon 600 Missense, and NRAS Mutation are the most common alterations in thyroid gland adenocarcinoma .
There are 4 clinical trials for thyroid gland adenocarcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain thyroid gland adenocarcinoma as an inclusion criterion, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 2 are no phase specified (2 open).
BRAF is the most frequent gene inclusion criterion for thyroid gland adenocarcinoma clinical trials .
18f-tetrafluoroborate is the most common intervention in thyroid gland adenocarcinoma clinical trials.
Significant Genes in Thyroid Gland Adenocarcinoma
BRAF is altered in 42.82% of thyroid gland adenocarcinoma patients .
BRAF is an inclusion eligibility criterion in 3 clinical trials for thyroid gland adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.